Radiation sensitivity of esophageal adenocarcinoma: The contribution of the RNA-binding protein RNPC1 and p21-mediated cell cycle arrest to radioresistance

Radiation Research

Volumn 177, Issue 3, 2012, Pages 272-279

  Htte, Gijsbert J ^a,b   Linam Lennon, Niamh ^a   Reynolds, John V ^a   Maher, Stephen G ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; PROTEIN P21; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MESSENGER RNA; RBM38 PROTEIN, HUMAN; RNA BINDING PROTEIN;

ARTICLE; CANCER RADIOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE MICROSCOPY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; RADIOSENSITIVITY; RNPC1 GENE; ADENOCARCINOMA; CELL CYCLE CHECKPOINT; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RADIATION DOSE; TUMOR CELL LINE;

ADENOCARCINOMA; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESOPHAGEAL NEOPLASMS; G0 PHASE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RADIATION TOLERANCE; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84859928841     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2776.1     Document Type: Article

References (21)

1. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25:1160-8. (Pubitemid 46640561)
2. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8:226-34. (Pubitemid 46291702)
3. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23:2310-7. (Pubitemid 46218723)
4. Gaast A vHP, Hulshof M, Richel D, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol. 2010, 28:7s.
5. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001; 88:338-56. (Pubitemid 32238694)
6. Semrau R, Vallbohmer D, Holscher AH, Muller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009; 80:1035-41.
7. Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007; 245:707-16. (Pubitemid 46684100)
8. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemo-radiation. Cancer 2005; 103:1347-55. (Pubitemid 40410728)
9. Theisen J, Krause B, Peschel C, Schmid R, Geinitz H, Friess H. Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer. World J Gastrointest Surg 2009; 1:30-7.
10. Maher SG, Gillham CM, Duggan SP, Smyth PC, Miller N, Muldoon C, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg 2009; 250:729-37.
11. Cho SJ, Zhang J, Chen X. RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability. Nucleic Acids Res 2010; 38:2256-67.
12. Shu L, Yan W, Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, is required for maintaining the stability of the basal and stress-induced p21 transcript. Genes Dev 2006; 20:2961-72. (Pubitemid 44771731)
13. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010; 16:376-83.
14. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966; 29:450-74.
15. Terasima T, Tolmach LJ. Variations in several responses of HeLa cells to x-irradiation during the division cycle. Biophys J 1963; 3:11-33.
16. Alvarez H, Koorstra JB, Hong SM, Boonstra JJ, Dinjens WN, Foratiere AA, et al. Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line. Cancer Biol Ther 2008; 7:1753-5.
17. Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJ, et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 2010; 103:1788-93.
18. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009. (Pubitemid 35461656)
19. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNI-CON phase II trial. Lancet Oncol 2007; 8:797-805. (Pubitemid 47308659)
20. Cazzalini O, Scovassi AI, Savio M, Stivala LA, Prosperi E. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res 2010; 704:12-20.
21. Zhang J, Jun Cho S, Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc Natl Acad Sci USA 2010; 107:9614-9.